Inside Stayble: October 2020

14 October 2020

In the October 2020 edition, CEO Andreas Gerward, covers the progress of the clinical phase IIb study with STA363, importance of participating in Eurospine congress, recruitment process of a CCO, upcoming partnering and investor events – and more.

Inside Stayble is a new communication channel aiming to provide shareholders with monthly updates about the Stayble Therapeutics and the clinical development program for STA363 in chronic low back pain.

Stayble Therapeutics is listed on Nasdaq First North in Sweden (STABL).